Aztreonam

Modify Date: 2024-01-02 13:05:04

Aztreonam Structure
Aztreonam structure
Common Name Aztreonam
CAS Number 78110-38-0 Molecular Weight 435.433
Density 1.83 Boiling Point N/A
Molecular Formula C13H17N5O8S2 Melting Point 227°C
MSDS Chinese USA Flash Point N/A

 Use of Aztreonam


Aztreonam is a synthetic monocyclic beta-lactam antibiotic, which has a very high affinity for penicillin-binding protein 3 (PBP-3).Target: Penicillin-binding proteins 3 (PBP-3)Aztreonam is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. It was approved by the U.S. Food and Drug Administration in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. Aztreonam has no useful activity against gram-positive or anaerobic microorganisms Aztreonam is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. Aztreonam is bactericidal but less so than some of the cephalosporins

 Names

Name aztreonam
Synonym More Synonyms

 Aztreonam Biological Activity

Description Aztreonam is a synthetic monocyclic beta-lactam antibiotic, which has a very high affinity for penicillin-binding protein 3 (PBP-3).Target: Penicillin-binding proteins 3 (PBP-3)Aztreonam is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. It was approved by the U.S. Food and Drug Administration in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. Aztreonam has no useful activity against gram-positive or anaerobic microorganisms Aztreonam is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. Aztreonam is bactericidal but less so than some of the cephalosporins
Related Catalog
References

[1]. Kobayashi Y, et al. Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood. J Antimicrob Chemother. 1992 Dec;30(6):871-2.

[2]. Guay DR, et al. Aztreonam, a new monobactam antimicrobial. Clin Pharm. 1985 Sep-Oct;4(5):516-26.

 Chemical & Physical Properties

Density 1.83
Melting Point 227°C
Molecular Formula C13H17N5O8S2
Molecular Weight 435.433
Exact Mass 435.051849
PSA 238.20000
LogP -0.66
Index of Refraction 1.74

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UA2451400
CHEMICAL NAME :
Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sul fo-3-azetidinyl)amino )- 2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2-alpha,3-beta(Z)))-
CAS REGISTRY NUMBER :
78110-38-0
LAST UPDATED :
199612
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C13-H17-N5-O8-S2
MOLECULAR WEIGHT :
435.47

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 18,474,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2549 mg/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay) Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),143,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3154 mg/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay) Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),143,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2001 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 19,468,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 18,474,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2897 mg/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay) Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),143,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3906 mg/kg
TOXIC EFFECTS :
Behavioral - changes in motor activity (specific assay) Skin and Appendages - hair Nutritional and Gross Metabolic - body temperature decrease
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),143,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1963 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),143,1985 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
21 gm/kg/35D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in bladder weight Skin and Appendages - dermatitis, other (after systemic exposure) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),169,1985
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
26250 mg/kg/35D-C
TOXIC EFFECTS :
Liver - changes in liver weight Blood - changes in erythrocyte (RBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),149,1985 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
2970 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),203,1985
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
1100 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
REFERENCE :
NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 33(Suppl 1),203,1985

 Safety Information

Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xn
Risk Phrases 20/21/22-36/37/38
Safety Phrases S22-S24/25
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS UA2451400
HS Code 2942000000

 Synthetic Route

~72%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: BIOGAL GYOGYSZERGYAR RT.; TEVA PHARMACEUTICAL USA, INC. Patent: WO2004/13133 A1, 2004 ; Location in patent: Page 10 ;

~80%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: Singh, Janak; Denzel, Theodor W.; Fox, Rita; Kissick, Thomas P.; Herter, Rolf; Wurdinger, Joseph; Schierling, Peter; Papaioannou, Chris G.; Moniot, Jerome L.; Mueller, Richard H.; Cimarusti, Christopher M. Organic Process Research and Development, 2002 , vol. 6, # 6 p. 863 - 868

~%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: US4826973 A1, ;

~%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: Singh, Janak; Denzel, Theodor W.; Fox, Rita; Kissick, Thomas P.; Herter, Rolf; Wurdinger, Joseph; Schierling, Peter; Papaioannou, Chris G.; Moniot, Jerome L.; Mueller, Richard H.; Cimarusti, Christopher M. Organic Process Research and Development, 2002 , vol. 6, # 6 p. 863 - 868

~%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: Organic Process Research and Development, , vol. 6, # 6 p. 863 - 868

~%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: Organic Process Research and Development, , vol. 6, # 6 p. 863 - 868

~%

Aztreonam Structure

Aztreonam

CAS#:78110-38-0

Literature: Heterocycles, , vol. 21, # 1 p. 191 - 210

 Customs

HS Code 2942000000

 Articles36

More Articles
Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins.

J. Allergy Clin. Immunol. 135(4) , 972-6, (2015)

Studies performed on samples larger than 100 subjects with a documented IgE-mediated hypersensitivity to penicillins have demonstrated a cross-reactivity rate of approximately 1% between penicillins a...

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Antimicrob. Agents Chemother. 59(1) , 467-74, (2014)

AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus epiderm...

An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.

Antimicrob. Agents Chemother. 58(12) , 7225-33, (2014)

Nitrofurantoin has been used for decades for the treatment of urinary tract infections (UTIs), but clinically significant resistance in Escherichia coli is uncommon. Nitrofurantoin concentrations in t...

 Synonyms

2-({[(1Z)-1-(2-Amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid
CAYSTON
Nebactam
[2S-[2a,3b(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic Acid
Azteronam
SQ 26,776
(2S,3S)-3-{[(2Z)-2-(2-Ammonio-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-2-methyl-4-oxoazetidine-1-sulfonate
MFCD00072145
sq26,776
Azactam
Primbactam
(2S,3S)-3-{[(2Z)-2-(2-Ammonio-1,3-thiazol-4-yl)-2-{[(2-carboxy-2-propanyl)oxy]imino}acetyl]amino}-2-methyl-4-oxo-1-azetidinesulfonate
EINECS 278-839-9
Aztreon
Azonam
Azthreonam
Propanoic acid, 2-[[[(1Z)-1-(2-amino-4-thiazolyl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl-
Aztreonam
monobactam
Top Suppliers:I want be here



Get all suppliers and price by the below link:

Aztreonam suppliers


Price: $106/10mM*1mLinDMSO

Reference only. check more Aztreonam price